BioAge LabsBIOA shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, a potential rival to Eli Lilly'sLLY takeover play Ventyx BiosciencesVTYX. BioAge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results